This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo
by Zacks Equity Research
Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.
How Potent Are JNJ & Other COVID-19 Jabs Against Delta Variant?
by Kinjel Shah
All available vaccines are mostly more effective against the Delta variant after two doses, and less effective after the first dose.
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer
Is BioNTech SE Sponsored (BNTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BNTX) Outperforming Other Medical Stocks This Year?
Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag
by Zacks Equity Research
Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
Horizon (HZNP) Begins Phase II Study for Lupus Candidate
by Zacks Equity Research
Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.
Moderna (MRNA) COVID-19 Vaccine Effective Against Delta Variant
by Zacks Equity Research
Moderna's (MRNA) share price reaches all-time high, following authorization from the government of India for mRNA-1273 and encouraging neutralizing activity against several COVID-19 variants demonstrated in studies.
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
by Zacks Equity Research
Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.
Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.
BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism
by Zacks Equity Research
Biomarin Pharmaceutical (BMRN) receives positive recommendation from Europe's CHMP for vosoritide to treat achondroplasia in children.
Walgreens (WBA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Faster adoption of digital health and improved business environment are expected to have contributed to Walgreens' (WBA) third-quarter performance.
AstraZeneca (AZN) Rare Disorder Drug Koselugo Gets EU Nod
by Zacks Equity Research
AstraZeneca's (AZN) Koselugo becomes the first medicine approved in Europe for neurofibromatosis type 1 plexiform neurofibromas.
Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?
by Zacks Equity Research
The new variant of COVID-19 virus, delta, is increasing the risk of infections across the globe. This will likely lead to higher demand for COVID-19 vaccines and therapeutics.
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate
by Zacks Equity Research
Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
by Zacks Equity Research
Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.
Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US
by Zacks Equity Research
Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.
Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BNTX) Outperforming Other Medical Stocks This Year?
Are You Looking for a Top Momentum Pick? Why BioNTech SE Sponsored ADR (BNTX) is a Great Choice
by Zacks Equity Research
Does BioNTech SE Sponsored ADR (BNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks
by Zacks Equity Research
Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate. Shares fall.
Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate
by Zacks Equity Research
Vertex (VRTX) to discontinue further development of AATD candidate, VX-864, as it appears unlikely to benefit patients.
COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart
by Indrajit Bandyopadhyay
The CDC reports cases of myocarditis and pericarditis following inoculation with mRNA vaccines of Moderna (MRNA) and Pfizer (PFE). The authority schedules meeting next week to investigate these reports.
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
by Kinjel Shah
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.